HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that it has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its HeartBeam System as a tool for assessing potential heart attacks at home. The designation recognizes the potential of HeartBeam's 3D ECG technology to enable physicians to evaluate signs of a possible heart attack when symptoms begin, regardless of the patient's location.
The FDA granted the designation within 30 days of HeartBeam's request, ahead of the agency's 60-day statutory review period. This expedited review underscores the importance of the technology. The designation provides prioritized FDA review and interaction as HeartBeam advances its heart attack assessment program, and it is a prerequisite for certain expedited Medicare coverage pathways. The company expects to seek FDA alignment on the design of a multicenter pivotal study in the coming months and anticipates beginning patient enrollment shortly thereafter. If successful, the study is intended to support a future submission to expand the HeartBeam System indications to include heart attack assessment.
HeartBeam's technology is designed to be a cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform is intended for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement.
The Breakthrough Device Designation is significant because it could accelerate the availability of a tool that allows for earlier detection of heart attacks, which is critical for improving patient outcomes. Heart attacks are a leading cause of death worldwide, and timely intervention is essential. By enabling at-home assessment, HeartBeam's technology could reduce delays in diagnosis and treatment, potentially saving lives and reducing healthcare costs. The designation also positions HeartBeam for expedited Medicare coverage, which could facilitate reimbursement and adoption once the technology is approved.
Investors and industry observers can find more details about HeartBeam (NASDAQ: BEAT) through the company's newsroom at https://nnw.fm/BEAT. The full press release is available at https://nnw.fm/FxKxf. For information on the intended use of the HeartBeam System, refer to https://www.heartbeam.com/indications.
NetworkNewsWire (NNW), a specialized communications platform, published the announcement. NNW is part of the Dynamic Brand Portfolio at IBN, which offers access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For full terms of use and disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer.
